TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Novartis ( (NVS) ) has provided an update.
On November 24, 2025, Novartis announced that the FDA approved Itvisma, a gene replacement therapy for spinal muscular atrophy (SMA), making it the first of its kind available for children two years and older, teens, and adults. This approval marks a significant advancement in SMA treatment, offering a one-time dose that replaces the SMN1 gene, potentially reducing the need for chronic treatment. The therapy demonstrated improved motor function and stabilization in clinical trials, with a consistent safety profile. This development is expected to transform the care landscape for SMA and expand access to treatment for older patients, addressing unmet needs in the community.
The most recent analyst rating on (NVS) stock is a Buy with a $151.00 price target. To see the full list of analyst forecasts on Novartis stock, see the NVS Stock Forecast page.
Spark’s Take on NVS Stock
According to Spark, TipRanks’ AI Analyst, NVS is a Outperform.
Novartis presents a strong investment case with robust financial performance and positive earnings call highlights. The technical analysis supports a positive trend, though valuation metrics are moderate. The company’s strategic focus on innovation and expansion, despite some market challenges, underpins its growth potential.
To see Spark’s full report on NVS stock, click here.
More about Novartis
Novartis AG is a global healthcare company based in Switzerland, focusing on innovative medicines, particularly in the fields of neurology and genetic medicine. The company is known for its work in spinal muscular atrophy (SMA) and multiple sclerosis (MS), with a commitment to expanding treatment options in neuroimmunology, neurodegeneration, and neuromuscular diseases.
Average Trading Volume: 1,532,746
Technical Sentiment Signal: Buy
Current Market Cap: $242.5B
For an in-depth examination of NVS stock, go to TipRanks’ Overview page.